|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,682.30 INR | +0.46% |
|
+1.50% | +3.22% |
| 06-02 | Alkem Laboratories Limited Launches Semaglutide in Single-Shot Pre-Filled Syringes At Price Starting Inr 350 | CI |
| 06-02 | Alkem Laboratories Shows Strong Moves But Weak Follow-Through |  |
| Market Cap | 679B 7.05B 6.18B 5.73B 5.27B 9.94B 10.06B 68.36B 26.75B 333B 26.47B 25.9B 1,149B | P/E 2026 |
27.5x | P/E 2027 * | 29.1x |
|---|---|---|---|---|---|
| Enterprise Value | 651B 6.76B 5.93B 5.49B 5.05B 9.53B 9.64B 65.53B 25.64B 319B 25.38B 24.83B 1,102B | EV / Sales 2026 |
4.3x | EV / Sales 2027 * | 3.98x |
| Free-Float |
37.56% | Yield 2026 |
1% | Yield 2027 * | 0.9% |
Last Transcript: Alkem Laboratories Limited
| 1 day | +0.46% | ||
| 1 week | +1.50% | ||
| Current month | +2.00% | ||
| 1 month | +5.72% | ||
| 3 months | -0.28% | ||
| 6 months | +0.43% | ||
| Current year | +3.22% |
| 1 week | 5,543.2 |  | 5,730.85 |
| 1 month | 5,390.1 | | 5,733 |
| Current year | 5,085 | | 5,933 |
| 1 year | 4,740.65 | | 5,933 |
| 3 years | 3,440.05 | | 6,440 |
| 5 years | 2,835 | | 6,440 |
| 10 years | 1,400 | | 6,440 |
| Manager | Title | Age | Since |
|---|---|---|---|
Rajorshi Ganguli
PSD | President | - | - |
Akhilesh Sharma
PSD | President | - | - |
Nitin Agrawal
DFI | Director of Finance/CFO | - | 2024-01-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Sandeep Singh
BRD | Director/Board Member | 44 | 2013-08-08 |
| Director/Board Member | 63 | 2008-02-10 | |
Sarvesh Singh
BRD | Director/Board Member | 44 | 2019-11-10 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.46% | +1.50% | - | - | 7.01B | |
| +2.49% | +1.98% | +54.22% | +154.40% | 1,023B | |
| +0.72% | -1.28% | +52.48% | +47.25% | 599B | |
| +1.07% | +4.62% | +38.54% | +78.17% | 448B | |
| +0.63% | +2.08% | +30.59% | +21.56% | 326B | |
| +1.98% | +2.55% | +37.13% | +37.55% | 278B | |
| +0.90% | +1.04% | +22.09% | +15.99% | 258B | |
| -1.20% | +1.36% | -21.14% | -41.57% | 222B | |
| +0.57% | +3.09% | +23.78% | +55.97% | 197B | |
| -2.20% | +0.18% | +20.32% | +61.56% | 165B | |
| Average | +0.09% | +1.09% | +28.67% | +47.87% | 390.56B | |
| Weighted average by Cap. | -0.19% | +1.21% | +37.98% | +72.48% |
| 2026 | 2027 * | |
|---|---|---|
| Net sales | 146B 1.52B 1.33B 1.23B 1.14B 2.14B 2.17B 14.72B 5.76B 71.67B 5.7B 5.58B 247B | 165B 1.72B 1.51B 1.39B 1.28B 2.42B 2.45B 16.64B 6.51B 81.05B 6.45B 6.31B 280B |
| Net income | 25.13B 261M 229M 212M 195M 368M 372M 2.53B 990M 12.31B 979M 958M 42.52B | 23.59B 245M 215M 199M 183M 345M 349M 2.37B 929M 11.56B 919M 900M 39.92B |
| Net Debt | -28.13B -292M -256M -237M -218M -412M -417M -2.83B -1.11B -13.79B -1.1B -1.07B -47.61B | -21.73B -226M -198M -183M -169M -318M -322M -2.19B -856M -10.65B -847M -829M -36.77B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-21 | ₹5,682.30 | +0.46% | 1,765 |
| 26-07-20 | ₹5,656.55 | +1.87% | 3,332 |
| 26-07-17 | ₹5,552.90 | -2.64% | 1,913 |
| 26-07-16 | ₹5,703.50 | +0.64% | 4,344 |
| 26-07-15 | ₹5,667.45 | +1.23% | 4,289 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ALKEM Stock
- 539523 Stock
Select your edition
All financial news and data tailored to specific country editions
